![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Background: The burgeoning number of people with diabetes mellitus is a global problem. Simple but effective treatment with minimal side effects will be required to reduce the risk for macro- and micro-vascular complications. A big part of this goal can be achieved by the ready administration of insulin with or without other medications. Methods: The RapidMist™ drug delivery system places human recombinant insulin in a liquid formulation so as to be delivered to the buccal mucosa with an asthma-like device. As with nitroglycerin, the insulin PK-PD is very fast, thus affording flexibility. Conclusion: Serial data show clinical efficacy in Type 1 and Type 2 diabetes with at least non-inferiority to regular insulin.
Keywords::